Briacell Therapeutics CORP. (BCTXZ) — 8-K Filings

8-K Filings (25)

• BriaCell Therapeutics Files 8-K — Dec 29, 2025 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on December 29, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as A
• 8-K Filing — Dec 1, 2025
• BriaCell Therapeutics Corp. Files 8-K — Aug 26, 2025 Risk: medium
  BriaCell Therapeutics Corp. filed an 8-K on August 26, 2025, reporting an event that occurred on August 21, 2025. The filing indicates a change in the company's
• BriaCell Therapeutics Corp. Enters Material Definitive Agreement — Jul 16, 2025 Risk: medium
  BriaCell Therapeutics Corp. announced on July 15, 2025, that it entered into a material definitive agreement. The company, formerly known as Ansell Capital Corp
• BriaCell Therapeutics Files 8-K Report — Jun 18, 2025 Risk: low
  On June 16, 2025, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits
• BriaCell Therapeutics Corp. Signs Material Definitive Agreement — Apr 28, 2025 Risk: medium
  BriaCell Therapeutics Corp. announced on April 24, 2025, that it entered into a material definitive agreement. The company, previously known as Ansell Capital C
• BriaCell Therapeutics Files 8-K — Mar 12, 2025 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on March 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• BriaCell to Acquire Inovio Pharmaceuticals for $100M — Feb 13, 2025 Risk: medium
  BriaCell Therapeutics Corp. announced on February 12, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Inovio Pharmace
• BriaCell Therapeutics Holds Security Holder Vote — Feb 6, 2025 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on February 6, 2025, reporting on a meeting of security holders held on February 5, 2025. The filing indicates that mat
• BriaCell Therapeutics Corp. Files 8-K — Feb 5, 2025 Risk: medium
  BriaCell Therapeutics Corp. announced on February 3, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
• BriaCell Therapeutics to Acquire Inovio Pharmaceuticals — Jan 28, 2025 Risk: medium
  BriaCell Therapeutics Corp. announced on January 24, 2025, that it has entered into a definitive agreement to acquire all of the outstanding shares of Inovio Ph
• BriaCell Therapeutics Corp. Files 8-K — Jan 3, 2025 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on January 3, 2025, reporting other events and financial statements. The company, previously known as Ansell Capital Co
• BriaCell Therapeutics Corp. Files 8-K: Material Agreement & Equity Sales — Dec 13, 2024 Risk: medium
  On December 11, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securi
• BriaCell Therapeutics Names New Directors and CMO — Nov 25, 2024 Risk: medium
  BriaCell Therapeutics Corp. announced on November 23, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the compan
• BriaCell Therapeutics Files 8-K — Nov 1, 2024 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on November 1, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, former
• BriaCell Therapeutics Corp. Files 8-K: Material Definitive Agreement — Oct 2, 2024 Risk: medium
  On October 1, 2024, BriaCell Therapeutics Corp. entered into a material definitive agreement, the details of which are not fully disclosed in this filing but ar
• BriaCell Therapeutics Corp. Files 8-K — Oct 1, 2024 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on October 1, 2024, reporting other events and financial statements. The company, formerly known as Ansell Capital Corp
• BriaCell Therapeutics Corp. Files 8-K — Sep 12, 2024 Risk: medium
  BriaCell Therapeutics Corp. announced on September 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sal
• BriaCell Therapeutics Files 8-K — Sep 11, 2024 Risk: low
  BriaCell Therapeutics Corp. filed an 8-K on September 11, 2024, reporting other events and financial statements as of September 9, 2024. The company, formerly k
• BriaCell Therapeutics Faces Delisting Notice — Aug 23, 2024 Risk: high
  BriaCell Therapeutics Corp. filed an 8-K on August 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was for
• BriaCell Therapeutics Files 8-K — Jul 18, 2024 Risk: low
  On July 18, 2024, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• BriaCell Therapeutics Faces Delisting Concerns — Jul 5, 2024 Risk: high
  BriaCell Therapeutics Corp. filed an 8-K on July 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
• BriaCell Therapeutics Corp. Files 8-K — May 17, 2024 Risk: medium
  BriaCell Therapeutics Corp. announced on May 14, 2024, that it entered into a material definitive agreement. The company also reported other events and filed fi
• BriaCell Therapeutics to Acquire Lexo, Inc. for $10M — Apr 2, 2024 Risk: medium
  BriaCell Therapeutics Corp. announced on April 1, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of Lexo, Inc. f
• BriaCell Files 8-K on Shareholder Vote Matters — Jan 31, 2024
  BriaCell Therapeutics Corp. filed an 8-K on January 31, 2024, reporting an event on January 30, 2024, related to the submission of matters to a vote of security

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX